Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess Safety, Tolerability, and Renal Effects of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

NCT03449199 is registered in ClinicalTrials.gov with Teijin America, Inc. as lead sponsor.

NCT NCT03449199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03449199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess Safety, Tolerability, and Renal Effects of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
Lead sponsor
Teijin America, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 10, 2018
Completion date
June 4, 2019
Enrollment
130 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic kidney disease